BiotechTube

Camrelizumab + Placebos + Gemcitabine + Cisplatin

Phase 3UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Carcinoma

Conditions

Nasopharyngeal Carcinoma

Trial Timeline

Nov 13, 2018 → Dec 31, 2022

NCT ID
NCT03707509

About Camrelizumab + Placebos + Gemcitabine + Cisplatin

Camrelizumab + Placebos + Gemcitabine + Cisplatin is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Nasopharyngeal Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03707509. Target conditions include Nasopharyngeal Carcinoma.

What happened to similar drugs?

0 of 12 similar drugs in Nasopharyngeal Carcinoma were approved

Approved (0) Terminated (0) Active (12)
🔄CisplatinSun PharmaceuticalPhase 3
🔄Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
🔄5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
🔄CapecitabineSun PharmaceuticalPhase 3
🔄Nedaplatin + CisplatinSun PharmaceuticalPhase 3
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
🔄QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03707509Phase 3UNKNOWN

Competing Products

20 competing products in Nasopharyngeal Carcinoma

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
11
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
31
CisplatinSun PharmaceuticalPhase 3
36
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
36
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
47
CapecitabineSun PharmaceuticalPhase 3
36
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
31
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
40
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
47
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
47
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
39
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
47
Pemetrexed (Alimta)Eli LillyPhase 2
35
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
29
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
29
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
25
FamitinibJiangsu Hengrui MedicinePhase 2
35
ApatinibJiangsu Hengrui MedicinePhase 2
35
SHR-1210Jiangsu Hengrui MedicinePhase 2
35
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
28